Several specific and potent inhibitors have been developed and approved for clinical use. Examples include:
1. Imatinib: Used for treating chronic myeloid leukemia (CML), imatinib targets the BCR-ABL fusion protein that drives the disease. 2. Trastuzumab: This monoclonal antibody targets the HER2 receptor, which is overexpressed in certain breast cancers. 3. Gefitinib: An inhibitor of the epidermal growth factor receptor (EGFR) used in non-small cell lung cancer. 4. Vemurafenib: Targets the BRAF V600E mutation in melanoma. 5. Olaparib: A PARP inhibitor used in BRCA-mutated ovarian and breast cancers.
